Skip to main content

Four Reasons to Be Optimistic About Medicare

The most recent trustees’ report forecasts that the Medicare trust fund will be exhausted in 2030. While that is a financially frightening prospect, there was good news buried in the report: the previous forecast indicated the funds would be gone in 2026.
I believe there are reasons to be far more optimistic. Here’s why:
1.       There are cheaper medical services on the way. Theranos has a totally new approach to blood analysis as an example. Founded by Elizabeth Holmes, and backed by a who’s who, Theranos has micro labs that can be installed anywhere and only require a few drops of blood. Millions of us troop to a Quest Diagnostics center, or one of its competitors, to have our blood chemistry tested for any of thousands of things like cholesterol levels, hepatitis presence, insulin and blood sugar and so on. Quest, of course, bills the patient, and/or the patient’s insurer, including Medicare. Theranos is an example of a better, cheaper, faster option. While its new process must make it through the FDA approval minefield, I expect it will eventually become a real alternative, certainly before 2030. And, due to FDA leadership, the Obama administration or both, the FDA has actually shown some needed speed and flexibility recently.
2.       There are new ways to clean hospital rooms. There are a number of life-threatening illnesses that, from a practical point of view, can only be caught in a hospital or a nursing home. Nasty strains of pneumonia. The debilitating clostrium difficile. In its April 2013 report, Antibiotic Resistant Threats in the United States, the CDC estimates 23,000 Americans die each year from microbes that are resistant to current treatments. It states “The estimates are based on conservative assumptions and are likely minimum estimates”.  Many, if not most, of these deaths are a result of infections acquired in a hospital. Patients are treated with a series of more and more toxic (and expensive) antibiotics in hopes of curing the infection. Xenex Healthcare now provides robots that disinfect hospital rooms with high-intensity bursts of light. Savings to patients (copays and out-of-pockets), insurers and underwriters including Medicare should run into the billions.
3.       There are new antibiotics on the way. Again, treatment of patients infected with superbugs is expensive. Patients may be in high-cost intensive care units. Better antibiotics can prevent or reduce most of those costs. Most pharmaceutical companies have walked away from antibiotic research. From an investment viewpoint, that decision makes a lot of sense. FDA approval is gigantically expensive. If approved, an antibiotic may only be used for a few doses. And if patients are sickened, have reactions or die as a result of an antibiotic treatment, lawsuits are certain to follow. Therefore pharma has moved research to the treatment of chronic illnesses like diabetes, where they may have a customer for twenty years, thirty or even longer. But there are some firms that are investing in antibiotics. Northeastern University, in conjunction with NovoBiotic, have announced isolating Teixobactin, a soil-dwelling bacteria that doesn’t get along with MRSA (methicillin-resistant Staphylococcus aureus), one of the most evil superbugs. Testing so far indicates that Teixobactin is well-tolerated in mice and kills a variety of bad actors.
4.       Eventually, we hope that auditing will catch up with the bad guys. Years ago, some Medicare official stated that as much as ten percent of Medicare billings are fraudulent. Apparently that was based on pretty flimsy analysis. However, there is at least anecdotal reason to believe it could be more than ten percent – actually a lot more. Some future Congress and Administration will likely chose to apply the same data techniques that Visa, Mastercard and American Express apply to spot fraudulent card activity in seconds. That alone might be enough to add several more years of life to the trust fund.

While I’ve shown four reasons, in reality they boil down to fewer. Science and technology underlie all. That makes me optimistic that people will live longer and healthier, and Medicare won’t run out of money as fast as feared.

Comments

Popular posts from this blog

Book Review: What Matters Now by Gary Hamel

Interview of Eric Schmidt by Gary Hamel at the MLab dinner tonight. Google's Marissa Mayer and Hal Varian also joined the open dialog about Google's culture and management style, from chaos to arrogance. The video just went up on YouTube. It's quite entertaining. (Photo credit: Wikipedia)Cover of The Future of ManagementMy list of must-read business writers continues to expand.Gary Hamel, however, author of What Matters Now, with the very long subtitle of How to Win in a World of Relentless Change, Ferocious Competition, and Unstoppable Innovation, has been on the list for quite some time.Continuing his thesis on the need for a new approach to management introduced in his prior book The Future of Management, Hamel calls for a complete rethinking of how enterprises are run.

Fundamental to his recommendation is that the practice of management is ossified in a command and control system that is now generations old and needs to be replaced with something that reflects an educat…

Book Review- Stretch by Scott Sonenshein

Have you ever watched, or been involved in, a business failure, where, despite the best efforts of hardworking people, the business doesn’t survive? Scott Sonenshein lived through it, as he describes in the Introduction to his engrossing book Stretch.  (In some books, the reader can skip the intro- not this one; the introduction is a must-read part of the book.) He was hired by start-up Vividence in Silicon Valley at the very apex of the tech boom.  Despite prestige VC backers, top-tier hires and $50 million, Vividence didn’t make it. As his career continued, that experience led to an interest in why some well-funded operations don’t succeed, while other, more resource constrained, do. Peter Senge wrote about reinforcing cycles as part of his book The Fifth Discipline, which I consider one of the finest business books ever penned. In it, Senge describes the downward cycle that some companies fall into, and why it is so difficult to reverse. Sonenshein explores those cycles from diffe…

Tax Inversions

A savvy businessman once told me “it’s important to know what problem you are trying to solve”.
Let’s ignore for the moment whether or not Treasury or the IRS had the power to change the rules on so-called tax inversions without Congressional action. (The power they said they didn’t have only a few months ago.)
Rather, let’s focus on what problem we are trying to solve. That is, why is the greatest country on earth chasing companies away? Shouldn’t the U.S. be the place that companies want to locate their headquarters?
Imagine this: the U.S. legal structure and tax regime was so attractive that Mercedes, Toyota, Astra Zeneca, Samsung, Total, Singapore Air, Banco Santander, Petrobras, Fujitsu, Nokia, SAP, Audi, Tata Group, Lenovo, Pirelli, Deutsche Bank, Honda, LG, Hyundai, Roche, Credit Suisse, Four Seasons, Siemens, Phillips, Bridgestone, Anglo-America, DeBeers, Volkswagen, Canon,  L’OrĂ©al, Swatch, Armani, LVMH, Toshiba, H&M, Mahindra, Aldi, Kubota, Onex, Ducati, Pemex, Saudi-Ara…